We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going ...
To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...
Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...
The S&P 500 and Nasdaq both fell by a whopping 1.46 percent and 3.07 percent, respectively, over fears that China is ...
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...
Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...
JNJ beat Q4 estimates for both earnings and ... billion in aggregate option fees and milestone payments. The NYSE ARCA Pharmaceutical Index declined 1.6% in the past five trading sessions.
Pharmaceutical giant Johnson & Johnson grew its share prices by 4.14 percent to close at $152.89 apiece as investors took heart from an investment bank’s rating upgrade of the company.